The mechanism by which glucocorticoids induce GH expression between embryonic days 18 and 19 (E18 -19) in the fetal rat pituitary gland was examined with an in vitro organ culture system. Twentyfour hour incubation of E18 pituitary glands in serum-free medium containing either dexamethasone (DEX, or corticosterone (0.5-5 M) resulted in a conspicuous accumulation of GH messenger RNA (mRNA), whereas no spontaneous expression of GH mRNA was noted without glucocorticoid. Triiodothyronine (1 nM) alone weakly induced GH mRNA but increased the effect of DEX 2-fold. The GH mRNA accumulation was not observed after 5 or 10 h incubation with DEX. However, a 10-h incubation with DEX followed by 14 h chase incubation without DEX resulted in apparent induction of GH mRNA. The induction of GH mRNA by DEX was completely inhibited by puromycin.
T HE DIFFERENTIATION and development of GH cells
in the fetal rat pituitary gland depend largely upon functions of the pituitary specific nuclear transcription factor pit-1 (also known as GHF-1). Several studies have established that this POU-transcription factor is responsible for the cell type-specific expression of the GH gene and is also required for the survival and proliferation of GH cells in the fetal pituitary gland (1) (2) (3) (4) . Because pit-1 is expressed before GH (5), it is recognized as indicating of the specification of the GH cell phenotype, that is, the differentiation of GH progenitor cells (6) . The presence of such GH progenitors has also been suggested by Lew et al. (7) , who established a cell line that expresses pit-1 but does not express either GH or PRL. On the other hand, recent studies with sensitive immunocytochemistry (8) or RT-PCR (9) have revealed that GH expression in the fetal pituitary gland can first be detected at embryonic day 15 (E15) in rats. Thus, the initial GH expression appears to be taking place as soon as the pit-1 protein becomes available in some GH progenitors. However, the GH expression remains at an extremely low level until E19, when distinct GH expression is detectable with conventional Northern blot analyses (9) , reverse hemolytic plaque assay (10) , RIA (11) , and in situ hybridization (12) . The different parameters of GH synthesis in the fetal pituitary gland increase steeply from E19 on. For example, the pituitary GH content increases 58-fold from E19 to E21 (13) , and pituitary GH messenger RNA (mRNA) level increases 18-fold from E20 to E21 (9) . In contrast, the population of GH cells in the anterior pituitary gland as revealed by immunocytochemistry increases most notably between E18 and E19 (about 60-fold) (13) but shows little increase thereafter (10) . Therefore, we might consider the developmental process of the fetal GH cells to be divided into two distinct phases. In the first phase (before E19), a subset of pituitary cells are specialized to become GH cells probably owing to pit-1 expression, but many of them do not start to produce detectable amounts of GH. In the second phase (after E19), many GH progenitor cells develop into functionally active GH cells and pituitary GH production increases rapidly, mainly owing to an increase in GH production by individual GH cells rather than to an increase in the number of functional GH cells.
Our previous studies (13, 14) showed that this phase transition is normally achieved by the elevation of endogenous glucocorticoids level (15, 16) because administration of dexamethasone (DEX), a synthetic glucocorticoid, to pregnant rats results in the early induction of GH expression in E17 or E18 fetuses. However, the molecular mechanisms underlying the induction of GH synthesis by glucocorticoids in the fetal pituitary gland have not yet been investigated.
This study used an in vitro organ culture system to investigate the mechanisms of GH induction by glucocorticoids that occurs at a particular stage of gestation (between E18 and E19).
Materials and Methods
Timed-pregnant Sprague-Dawley rats obtained from CLEA Japan, Inc. (Tokyo, Japan) were acclimated for several days. Rats were housed in a temperature controlled (22 C) room with a light cycle of 14-h light, 10-h dark, and free access to food and tap water. The day on which spermatozoa were found in the vaginal smear was designated day 0 of pregnancy. Fetuses were removed from dams between 1000 h and 1200 h on days 16 -18 of gestation under light ether anesthesia. The fetal pituitary glands were removed under a surgical microscope and cut into several pieces with a razor blade. They were then incubated with 0.5 ml of ␣ modification of MEM (Flow Laboratories, Irvine, UK) supplemented with glutamine and antibiotics (control medium) in a 12-well plate. The E19 pituitaries were obtained similarly and stored at Ϫ80 C for the positive control of Northern analyses. DEX, T 3 , and puromycin (PM) (all from Sigma, St. Louis, MO) were used at 0.5-50 nm, 0.1 to 1 nm and 100 m, respectively. Tissues were incubated for 24 h unless stated and thereafter either stored frozen at Ϫ80 C for protein and mRNA analyses or fixed in 4% paraformaldehyde in 0.1 m phosphate buffer (PB), pH 7.4 at 4 C overnight for in situ hybridization.
In situ hybridization
Tissues fixed in paraformaldehyde were soaked in 20% sucrose in PB. The frozen section (7 m in thickness) was placed on a 3-aminopropylethoxysilane (Shin-Etsu Chemical Co., Ltd., Tokyo, Japan)-coated glass slide and air dried. The section was washed with diethylpyrocarbonate (DEPC, Sigma)-treated distilled water, digested with 0.1% pepsin (DAKO Japan Co., Ltd., Tokyo, Japan) in 0.2 n HCl at 37 C for 3 min, washed with DEPC-water, and dehydrated with ethanol. The section was hybridized with digoxigenin (DIG)-labeled rat GH complementary RNA (cRNA) (20 g/ml) in 50% formamide, 10 mm Tris, pH 7.5, 600 mm NaCl, 1 mm EDTA, 1 ϫ Denhardt's solution (0.02% each of BSA, polyvinylpyrrolidone, and Ficoll), 10% dextransulfate, 0.2 mg/ml yeast transfer RNA (tRNA), 0.1% sodium sarcosyl at 42 C overnight. After hybridization, the section was rinsed with 2 ϫ SSC (1 ϫ SSC ϭ 150 mm NaCl, 15 mm sodium citrate), then washed with 50% formamide/2 ϫ SSC at 55 for 60 min and incubated with 10 g/ml of RNase A (Sigma) in 10 mm Tris-HCl, pH 7.5, 0.5 m NaCl, at 37 C for 30 min. The section was washed with 0.2 ϫ SSC at 55 C for 60 min and incubated with alkaline phosphatase-labeled anti-DIG antibody (Boehringer Mannheim, GmbH, Germany), followed by alkaline phosphatase reaction to visualize the site of GH mRNA localization. The GH complementary DNA (cDNA) used for in situ hybridization (pGH-1) was kindly supplied by Dr. John D. Baxter, University of California, San Francisco, CA). The GH cDNA of about 800 bp was subcloned into a plasmid pGEM4Z (Promega Corporation, Madison, WI) and transcribed with either SP-6 or T7 polymerase (both from Takara Shuzo Co., Ltd., Shiga, Japan) to obtain antisense or sense cRNA probes, respectively.
RNA analysis
For Northern blot analysis, three to seven pituitary glands (depending on the age of the fetus) were pooled, and total RNA was isolated by the method described previously (17), followed by a phenol/chloroform extraction. The amount of total RNA was determined by densitometry and 5-10 g of RNA were separated on a 1% agarose gel containing formalin and transferred onto a nylon membrane (Hybond N ϩ , Amersham). The blot was hybridized with 32 P-labeled pGH-1 as previously described (13), washed, and exposed to x-ray film for 5-10 days. Then, the radioactive GH cDNA probe was removed and the filters were rehybridized with a rat 18s ribosomal RNA probe as a reference for the amount of RNA loaded on the gel. For quantification of the relative abundance of GH mRNA, the blots hybridized with 32 P-labeled probe were analyzed with an image analyzer (BAS2000; Fuji Film, Tokyo, Japan).
For the RNase protection assay, three pituitary glands were pooled, and total RNA was extracted as described above. A 125-bp fragment that encodes most of the sequences of the second exon of the rat GH gene was isolated from cloned rat GH gene prepared by Takeuchi et al. (18) and subcloned into a plasmid pGEM4Z (Promega Corporation, Madison, WI). The plasmid was linearized by HindIII digestion, and the 32 Plabeled cRNA probe was synthesized by SP-6 polymerase using 32 P-CTP (ICN Biomedicals, Inc., Costea Mesa, CA). A 221-bp rat pit-1 cDNA was obtained by RT-PCR from pituitary RNA of adult rats and cloned into the SmaI site of a plasmid pGEM4Z. This fragment contains sequences that correspond to 143-363 (from ATG) of rat pit-1 cDNA (1). The plasmid was linearized by EcoRI digestion and transcribed by T7-polymerase to give a cRNA probe. Both GH and pit-1 antisense cRNA probes contained about 60 bp of polylinker sequences. The sizes of the cRNA probes for GH and pit-1 are 185 and 283 bp, and expected sizes of protected fragments are 125 and 221 bp, respectively. Sequences of both probes were determined by the dideoxy chain termination method (19) to confirm identity with the authentic cDNA sequences. Pituitary RNA (5 g) was dissolved in 10 l of hybridization buffer (400 mm NaCl, 1 mm EDTA, 40 mm Pipes, pH 6.4, 80% formamide), and combined with the same volume of cRNA probes (3-5 ϫ 10 5 cpm) and incubated at 55 C for 4 h or overnight. After the hybridization, 150 l of digestion buffer composed of 300 mm sodium acetate, 5 mm EDTA, 10 mm Tris-HCl, pH 7.5, containing 10 g/ml of RNase A and 100 U/ml of RNase T 1 (both from Boehringer Mannheim) was added to the reaction mixture and incubated for 30 min at 37 C. Then, 2.5 l of Proteinase K (Boehringer Mannheim, 20 mg/ml) and 10 l of 10% SDS was added and incubated at 37 C for an additional 15 min. The protected fragments were precipitated and analyzed on a 6% polyacrylamide gel containing 8 m urea.
Immunoblot analyses
Pituitary glands were homogenized in 10 l per pituitary gland of 0.5% Nonidet P-40/PBS (5 mm PB pH 7.4/0.9% NaCl) and centrifuged at 15,000 rpm. The supernatant was combined with the same volume of 0.1 m Tris-HCl, pH 6.8, 4% SDS, 2% 2-mercaptoethanol, 0.1% bromphenolblue, 20% glycerol, and heated at 95 C for 10 min. Proteins were separated on a 15% polyacrylamide gel and electrophoretically transferred onto a nylon membrane (Immobilon-P, Millipore Corporation, Bedford, MA). The blot was sequentially incubated in 25% blocking reagent (Block Ace, Dainihon Seiyaku Co., Ltd., Tokyo, Japan)/5 mm Tris-HCl, pH 7.5 at room temperature for 4 h, in the first specific antiserum diluted with 10% blocking reagent/5 mm Tris-HCl, pH 7.5, at 4 C for overnight, and then in 10% blocking reagent containing 1:10000 diluted peroxidase-labeled antirabbit IgG goat IgG fraction (MBL Co., Ltd., Nagoya, Japan). The GH and pit-1 were visualized with chemiluminescence reagents (Dupont NEN, Boston, MA). The antiserum to rat GH was raised in a rabbit with rat GHB-7, which was supplied through the National Hormone and Pituitary Program (Baltimore, MD) and used at 1:50000 dilution. The antiserum to pit-1 was a gift from Dr. Michael G. Rosenfeld, Howard Hughes Medical Institute, and Eukaryotic Regulatory Biology Program, University of California, San Diego, and used at 1:4000 dilution. The specificity of both antisera was examined and published elsewhere (14, 20) .
All the experiments were carried out in triplicate or in quadruplicate, and representative data of experiments are shown.
Statistical analyses
The significance of difference of the data was determined by ANOVA followed by Student-Newman-Keuls test.
Results
In situ hybridization revealed a number of GH mRNApositive cells in the E18 fetal pituitary that has been incubated for 24 h in a control medium supplemented with 50 nm of DEX (Fig. 1B) . The intensity of staining varied to a large extent between cells. Positive cells were scattered throughout the anterior lobe. In contrast, no GH mRNA-containing cells were detected in the E18 pituitaries incubated in control medium alone (Fig. 1A) . Hybridization with the sense strand cRNA probe did not stain GH cells in either control or DEXtreated tissue (data not shown).
Northern blot analysis showed that the GH mRNA level in the DEX-treated E18 pituitary gland is nearly identical to that in intact E19 pituitary ( Figs. 2A and 3) . Incubation with 1 nm T 3 alone had little effect on GH mRNA level; however, the addition of both DEX and T 3 had a synergistic effect on GH mRNA induction, raising GH mRNA to a level twice as high as that of intact E19 pituitary (Fig. 3) . The induction of GH mRNA by DEX and the synergism of DEX and T 3 was also observed in E17 pituitaries; however, the levels of GH mRNA never exceeded that of intact E19 pituitary (Fig. 3) . GH mRNA was not detectable in E16 pituitary after incubation with DEX, indicating the paucity of DEX-responsive cells at this stage (data not shown). Induction of GH mRNA by DEX increased in a dose-dependent manner (Fig. 2B) , and corticosterone, a major circulating glucocorticoid in rats, was also capable of inducing GH mRNA in vitro (Fig. 2C) . Additionally, corticosterone acted synergistically with T 3 to induce GH mRNA (Fig. 2C) .
The time course of the GH mRNA induction by DEX was examined in E18 pituitaries (Fig. 4A) . Induction of GH mRNA induction was not observed after 5 or 10 h of incubation in medium containing DEX, but was evident after 24 h of incubation. However, a conspicuous GH mRNA induction occurred when tissues were exposed to DEX for 10 h, then incubated for an additional 14 h in DEX-free control medium. Five-hour incubation with DEX plus 19-h chase incubation in   FIG. 4 . RNase protection assay of pituitary GH mRNA. RNase(-), Total RNA from intact E18 pituitary gland was hybridized with 32 Plabeled cRNA probes, but RNase treatment was omitted to show the position of probes. tRNA, Yeast tRNA was used instead of the pituitary RNA sample for negative control. A, DEX induction of GH mRNA does not require the continuous presence of DEX. Total RNA obtained from three pituitary glands were analyzed with RNase protection assay. Incubation with DEX (50 nM) for 5 or 10 h did not induce GH mRNA in E18 pituitary gland but did induce GH mRNA after 24 h. Incubation with DEX for 5 or 10 plus chase incubation for 19 or 14 h in CM (DEX-free medium), respectively, resulted in GH mRNA accumulation. B, GH mRNA induction by DEX in E18 pituitary gland requires ongoing protein synthesis. Eight-hour incubation of E18 pituitary glands with DEX plus 16 h chase incubation with DEX-free medium resulted in GH mRNA induction (DEX 8 h ϩ CM 16 h); however, induction was inhibited by addition of 54 M of puromycin (PM) during the first 8-h incubation period (DEX/PM 8 h ϩ CM 16 h). Even when tissues were incubated with DEX plus PM for 8 h, GH mRNA was induced when DEX was added to the chase incubation medium (DEX/PM 8 h ϩ DEX 16 h), indicating that the effect of PM is not due to cytotoxicity.
FIG. 1. In situ hybridization of E18 pituitary glands from control (A)
or DEX-treated (B) fetus with rat GH cRNA. DEX treatment induced numerous GH mRNA positive cells, whereas positive cell were not seen in control tissue. Magnification, ϫ200.
FIG. 2.
Northern blot analyses of glucocorticoid induction of GH mRNA in E18 pituitary gland. CM, control medium; DEX, dexamethasone; CS, corticosterone. A, 24-hour incubation of E18 pituitaries with DEX (50 nM) resulted in GH mRNA accumulation in the tissue to a level similar to that in intact E19 pituitaries. T 3 (1 nM) had little effect on GH mRNA but enhanced the effect of DEX. B, GH mRNA induction by DEX in E18 pituitary gland is dose dependent. C, CS was also capable of inducing GH mRNA in E18 pituitary gland in a dosedependent manner, and T 3 acted synergistically with CS to induce GH mRNA. After the detection of GH mRNA, all blots were reprobed with an 18s ribosomal RNA probe (18s) for the reference of RNA loading. DEX-free medium also weakly induced GH mRNA. These results indicate that GH mRNA synthesis occurred in the absence of DEX and suggest the presence of a factor that is induced by DEX and mediate DEX action.
Subsequently, the effect of a protein-synthesis inhibitor on induction by DEX of GH mRNA was examined (Fig. 4B) . Incubation of E18 pituitaries with DEX for 8 h, followed by chace incubation in control medium for 16 h, resulted in GH mRNA induction. Addition of puromycin (54 m) to the medium with DEX for the first 8-h incubation period completely inhibited GH mRNA induction after the 16-h chase incubation. However, even if puromycin was present in the first 8-h incubation, a positive GH mRNA induction was observed when puromycin was washed out and DEX was added to the chase incubation, indicating that the pituitaries retained normal mechanisms for GH mRNA synthesis after puromycin treatment. The data illustrated in Fig. 4 taken as a whole suggest that the induction of GH mRNA in the fetal pituitary gland by DEX requires ongoing protein synthesis and that the action of DEX may be mediated by a factor or factors produced in the pituitary gland in response to DEX. Because DEX is reported to enhance pit-1 production in a synergistic manner with a protein kinase C activator (21) and pit-1 is required for GH transcription (1), the change in pit-1 expression in the fetal pituitary gland by DEX was examined. Immunoblot analysis indicated that incubation of E18 pituitaries with DEX for 24 h increased pituitary GH concentration, whereas pituitary pit-1 remained constant (Fig. 5A ). In accordance with these results, the RNase protection assay revealed that GH mRNA but not pit-1 mRNA was enhanced by DEX treatment (Fig. 5B) .
Discussion
The induction of GH by glucocorticoids in the fetal rat pituitary gland was successfully reproduced in this study with an in vitro serum-free culture system. The present culture system is considered an appropriate model with which to study the steps in the terminal maturation of GH cell that occurs between E18 and E19 in utero for the following reasons. First, the GH mRNA level in the E18 pituitary gland after 24 h of incubation with DEX (corresponding to E19 in utero) is nearly identical to that in E19 intact pituitaries. Second, the physiological dose of corticosterone, a major endogenous glucocorticoid in rats, was also capable of inducing GH mRNA. The lower dose of corticosterone examined in this study was 0.5 m (or 17.3 g/dl), which resulted in a distinct GH mRNA induction. This dose falls within the range of the fetal plasma level, which varies from 5 to 10 g/dl at E16 to 30 to 45 g/dl at E19, when it reaches a peak during the transient elevation that occurs in late gestation (15, 16) . It is also indicated in this study that the glucocorticoid is the only requirement for GH progenitors at E18 to initiate GH mRNA production in vitro because the present culture system did not contain any hormonal component except DEX.
The present results also indicate that the primary site of glucocorticoid action is the pituitary gland and that the participation of maternal factors, the placenta or the fetal hypothalamus, are not prerequisite for the initiation of GH production in the fetal pituitary gland. This finding is consistent with the results of Hemming et al. (22, 23) , who showed with an organ culture system of E14 pituitary primordia that the development of GH cells in vitro requires cortisol. The present results extend their findings by specifying the stage of GH cell development at which glucocorticoids are required. On the other hand, thyroid hormone appears to be less important than DEX for the induction of GH expression in the fetus at this stage, despite its distinct effect on GH transcriptional activation in the adult rat (24) and in pituitary tumor cells (25, 26) , a finding that suggest the presence of an intrinsic regulatory mechanisms for GH expression during the fetal period.
Because the GH mRNA level is extremely low at E18 (before DEX-treatment), the increase in the GH mRNA level in response to DEX is considered to be primarily due to activation of GH transcription. However, unlike the human GH gene (27, 28) , a distinct glucocorticoid response element is not present in the 5Ј-upstream region of the rat GH gene, suggesting that DEX-glucocorticoid receptor complex might not directly modulate GH gene transcription in rats. Indeed, in other systems, the effect of DEX on the activation of GH gene transcription is negative or extremely weak and cannot account for the marked increase in GH mRNA accumulation induced by this steroid (29) . The stabilization of GH mRNA is also a proposed mechanism of DEX-induced GH mRNA accumulation (30) . The data illustrated in Fig. 4 , indicating that the effect of DEX is time dependent and puromycin sensitive, lead us to postulate the presence of a factor that is synthesized in response to DEX and activates GH gene expression. Once this factor is accumulated in the gland, the continuous presence of DEX is not required, suggesting that this factor is stable with a relatively long half-life. Another explanation for the inhibitory effect of puromycin on the GH mRNA induction is that puromycin reduced the level of a rapidly turned over protein, which is already present in E18 pituitary gland and is required for the activation of GH transcription. The nature of the factor is still unknown. Several nuclear proteins are known to interact with the promoter/enhancer region of the rat GH gene (6, 31) , but only the thyroid hormone receptor, pit-1, and Zn-15 have been demonstrated to activate the rat GH gene (1, 25, 32) . Because DEX induces GH mRNA expression without thyroid hormone, as demonstrated in this study, the thyroid hormone receptor cannot be the factor that mediates DEX action. Zn-15 (32) is a newly characterized nuclear protein that is expressed both in the pituitary gland and in several nonpituitary tissues. The sequences between the proximal and distal pit-1 binding sites of rat GH promoter have been shown to be important for normal GH expression in rats and are bound by Zn-15 to enhance pit-1-dependent GH transcription (32) . Therefore, it is possible to postulate Zn-15 as a mediator of DEX action, although it is still unknown whether glucocorticoid is responsible for the regulation of Zn-15 synthesis.
Pit-1 is a primary requirement for GH transcription (1). In the adult pituitary, stimulation of GH secretion by several secretagogues accompany an apparent increase in the pituitary pit-1 level (33) . Therefore, activation of pit-1 production may be responsible for the increase in GH transcription. Furthermore, Jong et al. (21) demonstrated the synergistic activation of pit-1 gene transcription by DEX and protein kinase C activator in GH 4 C 1 cells. The mechanism of this reaction resembled that of the induction of GH mRNA by DEX in the fetal pituitary gland with respect to the presence of an unknown factor or factors that mediate action of DEX. However, the lack of changes in the levels of pit-1 and pit-1 mRNA after DEX, irrespective of the conspicuous increases in the levels of GH and GH mRNA, suggests that the change in the pit-1 level is not involved in the mechanisms of DEX action in the fetal pituitary gland.
The mechanism by which GH expression is stimulated by a DEX-induced factor is obscure. The factor may directly activate GH transcription through the interaction with an unknown cis-element on the GH promoter or enhancer region or may exert its effect by modifying the nuclear protein(s) to alter their ability to stimulate GH transcription. The factor might also enhance GH transcription through modification of local chromatin structure. In vivo footprinting experiments revealed that the promoter region (GHF-1/pit-1 binding site) of the GH gene of GH-producing cells are sensitive to nuclease digestion, whereas that of non-GHproducing cells is not (6) . Another possibility is that the DEX-induced factor removes inhibitory controls for GH expression. Activins (34), insulin (35) , and insulin-like growth factor (36) are all known to suppress pituitary GH expression. If the GH gene is inactivated before E19 by one or more of these substances, the removal of these negative control by DEX-induced factor would enhance GH expression.
As glucocorticoid receptor has been demonstrated in multiple types of pituitary cells, the types of cells that are targets of DEX were not specified in this study. If immature GH cells are targets of DEX, the mechanisms of DEX action might be as described above. On the other hand, DEX might stimulate other types of pituitary cells to secrete a substance, which, in turn, stimulates GH expression in a paracrine fashion. Expression of glucocorticoid receptor mRNA in the anterior pituitary gland was noted as early as E15 in rats, and at E17, when no GH cells have yet developed, some of the cells expressing glucocorticoid receptor are demonstrated by immunocytochemistry to be ACTH cells (37) .
In conclusion, the present results suggest that glucocorticoid plays a principal role in the induction of GH mRNA in the E18 pituitary gland. The induction of GH mRNA by glucocorticoids is mediated by an unknown factor that is produced in the pituitary gland in response to glucocorticoid stimulation and is probably involved in the activation of GH gene transcription.
